Identification
- Summary
Potassium Iodide is an oral antithyroid agent used for the prevention of radioactive iodine uptake into the thyroid gland during a nuclear radiation emergency.
- Brand Names
- Iosat, Pregvit, Thyrosafe, Thyroshield, Xylocaine With Epinephrine
- Generic Name
- Potassium Iodide
- DrugBank Accession Number
- DB06715
- Background
Saturated solution of Potassium Iodide (SSKI) is used pharmaceutically for emergency use in patients experiencing acute symptoms of severe hyperthyroidism (also known as thyroid storm or thyrotoxic crisis). SSKI can also be used for radioiodine-contamination emergencies or in preparation of thyrotoxic patients for thyroidectomy.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Potassium Iodide (DB06715)
- Weight
- Average: 166.0028
Monoisotopic: 165.868175281 - Chemical Formula
- IK
- Synonyms
- Kaliumiodid
- KI
- Potasio ioduro
- Potassium Iodide
- External IDs
- NSC-77362
Pharmacology
- Indication
Potassium Iodide is oral antithyroid agent used in the prevention of radioactive iodine uptake into the thyroid gland during a nuclear radiation emergency. Potassium Iodide may be used as an adjunct to other antithyroid agents in the treatment of hyperthyroidism and thyrotoxicosis and preoperatively to induce thyroid involution.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to prevent Folate deficiency Combination Product in combination with: Ferrous fumarate (DB14491), Folic acid (DB00158) ••• ••• •••••••• ••••• Used as adjunct in combination to prevent Goitre Combination Product in combination with: Levothyroxine (DB00451) •••••••••••• •••••• Used in combination to treat Goitre Combination Product in combination with: Levothyroxine (DB00451) •••••••••••• •••••• Used in combination to treat Hypothyroidism Combination Product in combination with: Levothyroxine (DB00451) •••••••••••• •••••• Used in combination to treat Iodine deficiency Combination Product in combination with: Iodine (DB05382) ••• ••• •••••••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
It works in the thyroid gland. By inhibiting thyroid hormone synthesis and release, thyroid gland vascularity is reduced, thyroid gland tissue becomes firmer, thyroid cell size is reduced, follicular colloid reaccumulates, and bound iodine levels increase. As a protectant following radiation exposure, KI blocks the uptake of radioactive iodine isotopes by the thyroid gland thereby minimizing the risk of radiation-induced thyroid neoplasms.
- Mechanism of action
Target Actions Organism UTyrosine binderHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab Potassium Iodide may increase the anticoagulant activities of Abciximab. Acalabrutinib The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Acalabrutinib. Acebutolol Potassium Iodide may increase the hyperkalemic activities of Acebutolol. Aceclofenac Potassium Iodide may increase the hyperkalemic activities of Aceclofenac. Acemetacin Potassium Iodide may increase the hyperkalemic activities of Acemetacin. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Active Moieties
Name Kind UNII CAS InChI Key Potassium cation ionic 295O53K152 24203-36-9 NPYPAHLBTDXSSS-UHFFFAOYSA-N Iodide ionic 09G4I6V86Q 20461-54-5 XMBWDFGMSWQBCA-UHFFFAOYSA-M - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Potassium Iodide Solution 1 g/1mL Oral Nivagen Pharmaceuticals, Inc. 2021-12-29 Not applicable US 
Potassium Iodide Solution 1 g/1mL Oral Laser Pharmaceuticals Inc. 2022-06-15 Not applicable US Sski Solution 1 g/1mL Oral Upsher-Smith Laboratories, LLC 1973-04-30 2019-06-30 US Sski Solution 1 g/1mL Oral Avondale Pharmaceuticals, Llc 2017-11-13 Not applicable US Sski Solution 1 g/1mL Oral Atlantic Biologicals Corp. 2017-11-13 Not applicable US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Iodine Capsule 0.22 mg Oral Thorne Research Inc. 1997-09-09 2006-08-04 Canada 
Iodine Ctr Srt 300mg Tablet, extended release 300 mcg / tab Oral Bioenergy Inc. 1979-12-31 1998-06-03 Canada Iodine Tab 0.5mg Tablet .5 mg / tab Oral Creative Nutrition Canada Corp. 1986-12-31 1998-07-16 Canada Iosat Tablet 65 mg/1 Oral Anbex Inc. 2013-05-01 Not applicable US Iosat Tablet 130 mg/1 Oral Anbex Inc. 1982-10-14 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image 24 Multivitamins + Minerals Potassium Iodide (.1 mg) + Ascorbic acid (150 mg) + Beta carotene (10000 unit) + Biotin (25 mcg) + Calcium (130 mg) + Cholecalciferol (400 unit) + Choline bitartrate (25 mg) + Chromium (20 mcg) + Copper (1 mg) + Cyanocobalamin (25 mcg) + Ferrous fumarate (15 mg) + Folic acid (.8 mg) + Inositol (25 mg) + Magnesium (65 mg) + Manganese (2 mg) + Molybdenum (20 mcg) + Niacin (25 mg) + Calcium pantothenate (25 mg) + Potassium (15 mg) + Pyridoxine hydrochloride (25 mg) + Racemethionine (25 mg) + Riboflavin (25 mg) + Selenium (20 mcg) + Thiamine hydrochloride (25 mg) + Vanadium (20 mcg) + Vitamin A palmitate (5000 unit) + Vitamin E (50 unit) + Zinc (10 mg) Tablet Oral Stanley Pharmaceuticals, A Division Of Vita Health Products Inc. 1997-04-30 2002-07-31 Canada 50 Plus Multiple Vitamins & Minerals Potassium Iodide (0.15 mg) + Ascorbic acid (90 mg) + Biotin (45 mcg) + Calcium (200 mg) + Cholecalciferol (400 unit) + Chromium (10 mcg) + Copper (2 mg) + Cyanocobalamin (25 mcg) + Folic acid (0.4 mg) + Magnesium (100 mg) + Manganese (5 mg) + Molybdenum (25 mcg) + Nicotinamide (40 mg) + Pantothenic acid (10 mg) + Pyridoxine hydrochloride (3 mg) + Riboflavin (3.2 mg) + Selenium (25 mcg) + Thiamine mononitrate (2.25 mg) + Vanadium (10 mcg) + Vitamin A palmitate (6000 unit) + Zinc (15 mg) Tablet Oral Gfr Pharma Ltd. 2002-10-20 2004-06-15 Canada ADDAMEL INFUSION N Potassium Iodide (166 mcg) + Chromic chloride hexahydrate (53.3 mcg) + Cupric chloride dihydrate (3.4 mg) + Ferric chloride hexahydrate (5.4 mg) + Manganese chloride tetrahydrate (990 mcg) + Sodium selenite pentahydrate (105 mcg) + Sodium fluoride (2.1 mg) + Sodium molybdate dihydrate (48.5 mcg) + Zinc chloride (13.6 mg) Solution, concentrate Intravenous FRESENIUS KABI COLOMBIA S.A.S. 2006-11-10 2009-05-08 Colombia 
ADDAMEL N Potassium Iodide (16.6 mcg/ml) + Chromic chloride hexahydrate (5.33 mcg/ml) + Cupric chloride dihydrate (0.1 mg/ml) + Ferric chloride hexahydrate (0.54 mg/ml) + Manganese chloride tetrahydrate (19.8 mcg/ml) + Sodium selenite (17.3 mcg/ml) + Sodium fluoride (0.21 mg/ml) + Sodium molybdate dihydrate (4.85 mcg/ml) + Zinc chloride (1.05 mg/ml) Injection, solution, concentrate Intravenous Fresenius Kabi Italia S.R.L. 2014-07-08 2020-05-12 Italy 
ADDAMEL N FOR INFUSION Potassium Iodide (16.6 mcg/ml) + Chromic chloride hexahydrate (5.33 mcg/ml) + Cupric chloride dihydrate (0.34 mg/ml) + Ferric chloride hexahydrate (0.54 mg/ml) + Manganese chloride tetrahydrate (99 mcg/ml) + Sodium selenite (6.9 mcg/ml) + Sodium fluoride (0.21 mg/ml) + Sodium molybdate dihydrate (4.85 mcg/ml) + Zinc chloride (1.36 mg/ml) Injection Intravenous FRESENIUS KABI (SINGAPORE) PTE LTD 1992-01-31 Not applicable Singapore 
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Abavite Potassium Iodide (0.25 mg/1) + Ascorbic acid (60 mg/1) + Cholecalciferol (0.025 mg/1) + DL-alpha tocopheryl acetate (13.5 mg/1) + Ferrous sulfate (30 mg/1) + Folic acid (1 mg/1) + Magnesium oxide (25 mg/1) + Mecobalamin (0.5 mg/1) + Niacin (15 mg/1) + Calcium pantothenate (5 mg/1) + Riboflavin (1.8 mg/1) + Thiamine mononitrate (1.6 mg/1) + Vitamin A palmitate (0.33 mg/1) + Zinc oxide (15 mg/1) Tablet Oral ABACOS HEALTH 2021-03-31 Not applicable US Addamel N Potassium Iodide (0.013 mg/1mL) + Chromic chloride hexahydrate (1 ug/1mL) + Cuprous chloride (0.13 mg/1mL) + Ferric chloride (0.11 mg/1mL) + Manganese chloride tetrahydrate (0.027 mg/1mL) + Sodium selenite (3.2 ug/1mL) + Sodium fluoride (0.095 mg/1mL) + Sodium molybdate dihydrate (1.9 ug/1mL) + Zinc chloride (0.65 mg/1mL) Injection, solution Intravenous Fresenius Kabi USA, LLC 2013-05-07 2017-03-31 US ADDAMEL N 20 AMPUL Potassium Iodide (166 mcg/10mL) + Chromic chloride (53.3 mcg/10mL) + Cupric Chloride (3.4 mg/10mL) + Ferric chloride (5.4 mg/10mL) + Manganese chloride (990 mcg/10mL) + Sodium selenite (69 mcg/10mL) + Sodium fluoride (2.1 mg/10mL) + Sodium molybdate (48.5 mcg/10mL) + Zinc chloride (13.6 mg/10mL) Injection, solution Intravenous FRESENİUS KABİ İLAÇ SAN. VE TİC. LTD. ŞTİ. 2019-04-30 Not applicable Turkey 
ADDAVEN IV INFUZYON ICIN KONSANTRE SOLUSYON Potassium Iodide (166 mcg/10mL) + Chromic chloride (53.3 mcg/10mL) + Cupric Chloride (1.02 mg/10mL) + Ferric chloride (5.4 mg/10mL) + Manganese chloride (198 mcg/10mL) + Sodium selenite (173 mcg/10mL) + Sodium fluoride (2.1 mg/10mL) + Sodium molybdate (48.5 mcg/10mL) + Zinc chloride (10.5 mg/10mL) Injection, solution Intravenous FRESENİUS KABİ İLAÇ SAN. VE TİC. LTD. ŞTİ. 2016-09-06 2022-11-10 Turkey BumP DHA Potassium Iodide (250 ug/1) + Cobamamide (500 mg/1) + Flavin adenine dinucleotide (1 mg/1) + Flavin mononucleotide (2 mg/1) + Iron (15 mg/1) + Leucovorin (1 mg/1) + Levomefolate magnesium (1 mg/1) + Magnesium oxide (125 mg/1) + NADH (25 ug/1) + Omega-3 fatty acids (300 mg/1) + Pyridoxal phosphate (5 mg/1) + Pyridoxine hydrochloride (20 mg/1) + Zinc glycinate (15 1/1) Capsule Oral Centurion Labs 2017-03-24 2017-04-17 US
Categories
- ATC Codes
- S01XA04 — Potassium iodide
- S01XA — Other ophthalmologicals
- S01X — OTHER OPHTHALMOLOGICALS
- S01 — OPHTHALMOLOGICALS
- S — SENSORY ORGANS
- V03AB — Antidotes
- V03A — ALL OTHER THERAPEUTIC PRODUCTS
- V03 — ALL OTHER THERAPEUTIC PRODUCTS
- V — VARIOUS
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as alkali metal iodides. These are inorganic compounds in which the largest halogen atom is Iodine, and the heaviest metal atom is an alkali metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Alkali metal salts
- Sub Class
- Alkali metal iodides
- Direct Parent
- Alkali metal iodides
- Alternative Parents
- Inorganic salts
- Substituents
- Alkali metal iodide / Inorganic salt
- Molecular Framework
- Not Available
- External Descriptors
- potassium salt (CHEBI:8346)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 1C4QK22F9J
- CAS number
- 7681-11-0
- InChI Key
- NLKNQRATVPKPDG-UHFFFAOYSA-M
- InChI
- InChI=1S/HI.K/h1H;/q;+1/p-1
- IUPAC Name
- potassium iodide
- SMILES
- [K+].[I-]
References
- Synthesis Reference
Stanley D. Lazarus, "Production of thermally stabilized polyester with alkylene carbonates and sodium or potassium iodide." U.S. Patent US4327207, issued October, 1973.
US4327207- General References
- Not Available
- External Links
- KEGG Drug
- D01016
- KEGG Compound
- C08219
- PubChem Compound
- 4875
- PubChem Substance
- 99443267
- ChemSpider
- 4709
- 8597
- ChEBI
- 8346
- ChEMBL
- CHEMBL1141
- PharmGKB
- PA451060
- Wikipedia
- Potassium_iodide
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Active Not Recruiting Treatment Dental Caries in Children 1 4 Completed Treatment Dental Decay 1 4 Completed Treatment Diabetic Macular Edema (DME) 1 4 Completed Treatment Graves' Disease / Hyperthyroidism 1 4 Completed Treatment Hyperemesis Gravidarum / Morning Sickness / Nausea / Pregnancy / Vomiting 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection Intravenous 5.33 mcg/ml Injection, solution Intravenous drip Solution Intravenous 5.33 mcg/ml Solution Intravenous Tablet, chewable Oral Bar, chewable Oral Capsule Oral Solution / drops Ophthalmic Tablet, extended release Oral Syrup Gel Oral Liquid Oral Liquid Topical Tablet, coated Oral Capsule Oral 0.22 mg Solution Topical Tablet, extended release Oral 300 mcg / tab Tablet Oral .5 mg / tab Solution Oral Tablet Oral 65 mg/1 Tablet Oral 0.131 mg Tablet Oral 0.196 mg Tablet Oral 0.262 mg Tablet Oral 2 mg Tablet Oral 100 µg Tablet Oral Tablet Oral 100 mcg Tablet Oral 200 mcg Tablet, effervescent Oral Liquid Intravenous Syrup Oral Capsule, gelatin coated; kit; tablet Oral Solution Intravenous 0.053 mg/10ml Injection, solution Intravenous Injection, solution, concentrate Intravenous; Parenteral Injection, solution, concentrate Parenteral Solution, concentrate Intravenous Injection Intravenous Powder Not applicable 1 kg/1kg Capsule, liquid filled; kit; tablet, coated Oral Capsule, liquid filled; kit; tablet Oral Capsule, gelatin coated Oral Pill Oral Injection, solution; kit; solution Infiltration; Perineural; Topical Tablet Oral 130 mg/1 Tablet Oral Kit Oral Powder Topical Solution Oral 1 g/1mL Solution / drops Oral Tablet Oral 0.09 mg Tablet Oral 130 mg Tablet Oral 65 mg Solution Oral 65 mg/1mL Injection, solution Parenteral Injection, solution, concentrate Intravenous Capsule, liquid filled Oral Capsule; kit; tablet Oral Tablet, film coated Oral Solution / drops Ophthalmic Powder Oral Solution Oral 1.5 g Tincture Topical Tablet, film coated Solution Tablet Oral 150 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP 0.2 Chemaxon pKa (Strongest Acidic) 3.09 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 0 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 0 m3·mol-1 Chemaxon Polarizability 1.78 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.7647 Blood Brain Barrier + 0.9702 Caco-2 permeable + 0.6625 P-glycoprotein substrate Non-substrate 0.8989 P-glycoprotein inhibitor I Non-inhibitor 0.984 P-glycoprotein inhibitor II Non-inhibitor 0.9854 Renal organic cation transporter Non-inhibitor 0.9282 CYP450 2C9 substrate Non-substrate 0.8261 CYP450 2D6 substrate Non-substrate 0.7789 CYP450 3A4 substrate Non-substrate 0.7857 CYP450 1A2 substrate Non-inhibitor 0.7164 CYP450 2C9 inhibitor Non-inhibitor 0.8527 CYP450 2D6 inhibitor Non-inhibitor 0.9142 CYP450 2C19 inhibitor Non-inhibitor 0.8842 CYP450 3A4 inhibitor Non-inhibitor 0.9317 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9022 Ames test Non AMES toxic 0.6838 Carcinogenicity Carcinogens 0.659 Biodegradation Not ready biodegradable 0.5913 Rat acute toxicity 2.9202 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9535 hERG inhibition (predictor II) Non-inhibitor 0.9657
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 113.819305 predictedDeepCCS 1.0 (2019) [M+H]+ 115.714714 predictedDeepCCS 1.0 (2019) [M+Na]+ 123.34075 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Unknown
Binder
References
- Pisarev MA, Aiello LO: Studies on the mechanism of action of potassium iodide on thyroid protein biosynthesis. Acta Endocrinol (Copenh). 1976 Jun;82(2):298-305. [Article]
- Foldes J, Gesztesi E, Juhasz J: Mechanism of action of di-iodotyrosine and of iodine. Acta Med Acad Sci Hung. 1974;31(1-2):131-7. [Article]
Drug created at May 16, 2010 23:39 / Updated at February 20, 2024 23:55